Harvey J. Berger, M.D.
@harveyjberger
Physician-Scientist & Serial Entrepreneur | Chair & CEO @KojinTx | Former Chair & CEO ARIAD | Board member, @DanaFarber & The Cameron Boyce Foundation | He/Him.
Incredible start to the newest chapter in my #biotech life. @KojinTx scientists are an amazing group, and I am proud to join them. Tame the fire for the good of humanity (the meaning of Kojin). @SchreiberStuart #ferroptosis
We are thrilled to announce the appointment of Dr. Harvey J Berger, a physician-scientist and biotech-industry veteran with 35 years of experience, as our new chairman and chief executive officer. For full details and to learn more about Dr. Berger: bwnews.pr/3TN3yIv
No greater voice in cardiology than Gene Braunwald. Single-dose gene editing to lower LDL for a lifetime may transform the care of patients with ASCVD. Key message: linear relationship between #LDL level and cardiac events. The lower the LDL, the better the long-term outcome.
What do cardiology KOLs think of Verve's vision of one dose to potentially lower LDL cholesterol for a lifetime? Found a key opinion leader :) 👇
Another example of insurance companies trying to practice medicine without training or patient insights. @Cigna, let’s get the scan and help cancer patients like @JohnCendpts.
Merkel cell carcinoma log, day #361 @Cigna has been giving my oncology team at @DanaFarber fits, refusing to cover my fourth Merkel cell carcinoma scan, marking the one-year anniversary of treatment. The scan is absolutely essential, as I've been unable - so far - to get a ctDNA…
The Moslehi Lab is now 10 years old! A few pics from the summer! Welcoming new members to the lab! We are still recruiting! Send me an email with your CV! @UCSFCardiology @UCSFCancer cardiooncologylab.ucsf.edu/moslehi-lab
The count down has begun! 1-week until the 1st FASEB Ferroptosis conference! Looking forward to seeing everyone at the meeting. Get excited!! 🤩 events.faseb.org/event/11797f9e…
Women’s #cancer research under siege. What differentiates #ovarian and #breast cancer from other cancers and how can they be detected early discussed by cell biologist @BruggeMe. 40 years of research in limbo.
This interview from the Soledad O'Brien Show captures some of the issues for women's health and our lab's cancer research affected by the termination of federal grants at Harvard and elsewhere youtube.com/watch?v=dtjZPt… @harvardmed @AACR
Many thanks to the @bodossaki Foundation for recognizing our lab's work!
Congratulations to Stavroula Hatzios @MCDB_Yale @YaleChem & Microbial Sciences Institute, who has been honored among distinguished scientists of Greek heritage by the @bodossaki Foundation. Full story: bit.ly/Hatzios-Bodoss…
The power of hematology & oncology clinical training at @DanaFarber — @jaybradner & Peter Marks — patient-centric discovery of new medicines. Being interviewed by @drcwestphal today at @kochinstitute.
Cancer has no boundaries — international collaborations are essential to ensure cancer patients worldwide are the beneficiaries of latest practice-changing discoveries. @LurieCancer #Greece @amanda_psyrri
With Drs. @amanda_psyrri & Popi Kalaitzi from University of Athens, who are visiting us in Chicago to discuss international collaborations between Northwestern Medicine and University of Athens. Along with Susan Helfrich, Vice President for International programs.
The best therapeutic targets start with well-validated human biology. Lower the scientific risk by ensuring the target reflects the disease and the clinical setting.
There's no free lunch in biotech. When you take less scientific risk by pursuing a more validated MoA, you're taking much more market risk from the increased competition. You're always trading off one type of risk for another.
$SMMT data highlight the uncertainty of predicting the outcome of large RCTs in complex diseases (cancer and beyond). New drug class clearly works but competitive positioning and regulatory path unclear at this time.
People are going to see into the $SMMT data what they want to see. 1) East-West reproducibility on PFS and impressive HR are encouraging 2) Lack of success on OS so far potentially jeopardizes the entire hypothesis - wouldn't be the first time it has happened. Pick your side
Telling it the way it is — from @kaelin_lab — about the importance of supporting fundamental research in the US. @DanaFarber
You want to hear the truth, and only the truth? You just tune in to @kaelin_lab again: amjmed.com/article/S0002-…
Let’s all rename the bill, “Reign In Unnecessary PBM Act” co-led by @RepAuchincloss of MA. This legislation would actually help control healthcare costs and do the right thing.
Now let's go national: Congress should pass the bipartisan, bicameral PBM Act that I am co-leading. statnews.com/pharmalot/2025…
Self-awareness of our limitations & self-accountability of the decisions we make as CEO scientists are key to successful biotech companies. Be decisive and own the consequences of our actions. Move quickly, focus on both safety & efficacy early on, and get to clinical POC fast.
I’m not a drug developer, but this is not the first time I hear this from you: The animal models have their faults. No matter how amazing they look, you can spend ten years perfecting them and still get it wrong! Having enough evidence, reassurance and belief before you get…
The ferroptosis hypothesis will be confirmed in the clinic. The challenge is finding funds to get there.
Wow 2 San Diego biotechs shutting down 🥲 That is disappointing- I was looking forward to seeing the ferraptosis hypothesis play out in the clinic with Kojin. Was also cheering for Stemson which looks like it is shutting down as well 💈
Biotech companies thrive on teamwork, innovation, and laboratory experimentation — much better in person than remote. We can learn from Chinese work ethic. Long hours in the lab.
Finally… 6. This should be a wake up call for US to support biotech with a favorable policy environment that fosters innovation and risk capital investment!